MX2014010574A - Preparacion solida oral de liberacion sostenida. - Google Patents
Preparacion solida oral de liberacion sostenida.Info
- Publication number
- MX2014010574A MX2014010574A MX2014010574A MX2014010574A MX2014010574A MX 2014010574 A MX2014010574 A MX 2014010574A MX 2014010574 A MX2014010574 A MX 2014010574A MX 2014010574 A MX2014010574 A MX 2014010574A MX 2014010574 A MX2014010574 A MX 2014010574A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained release
- solid preparation
- oral solid
- release oral
- gelling agent
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title abstract 7
- 239000012730 sustained-release form Substances 0.000 title abstract 7
- 238000002360 preparation method Methods 0.000 title abstract 5
- 239000007787 solid Substances 0.000 title abstract 5
- 239000003349 gelling agent Substances 0.000 abstract 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 2
- 229920000161 Locust bean gum Polymers 0.000 abstract 2
- 229960004372 aripiprazole Drugs 0.000 abstract 2
- 239000000711 locust bean gum Substances 0.000 abstract 2
- 235000010420 locust bean gum Nutrition 0.000 abstract 2
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 235000010493 xanthan gum Nutrition 0.000 abstract 2
- 229920001285 xanthan gum Polymers 0.000 abstract 2
- 239000000230 xanthan gum Substances 0.000 abstract 2
- 229940082509 xanthan gum Drugs 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
- 239000003431 cross linking reagent Substances 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000002772 monosaccharides Chemical class 0.000 abstract 1
- 150000005846 sugar alcohols Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Se provee una preparación sólida oral de liberación sostenida que comprende aripiprazol o una sal del mismo, como un ingrediente activo, y un método para producir la preparación sólida oral de liberación sostenida; una preparación sólida oral de liberación sostenida comprende aripiprazol o una sal del mismo y un excipiente de liberación sostenida; el excipiente de liberación sostenida comprende un gelificante; al menos un diluyente farmacéutico inerte, seleccionado del grupo que consiste en monosacáridos, disacáridos, alcoholes polihídricos y mezclas de los mismos y un agente de entrecruzamiento catiónico farmacéuticamente aceptable, capaz de entrecruzarse con el gelificante y de incrementar la resistencia del gel cuando la preparación sólida oral de liberación sostenida se expone a un fluido del ambiente, el gelificante comprende goma xantana y goma de algarrobilla, donde la relación de la goma xantana a la goma de algarrobilla en el gelificante es de aproximadamente 1:1 a 1:3 en peso, la relación del diluyente farmacéutico inerte al gelificante es de aproximadamente 1:1 a 1:2 en peso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607291P | 2012-03-06 | 2012-03-06 | |
| PCT/JP2013/056881 WO2013133448A1 (en) | 2012-03-06 | 2013-03-06 | Sustained release oral solid preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014010574A true MX2014010574A (es) | 2014-12-08 |
Family
ID=48014240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010574A MX2014010574A (es) | 2012-03-06 | 2013-03-06 | Preparacion solida oral de liberacion sostenida. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20150037424A1 (es) |
| EP (1) | EP2822989A1 (es) |
| JP (1) | JP2015509482A (es) |
| KR (1) | KR20140131987A (es) |
| CN (1) | CN104159949A (es) |
| AR (1) | AR090245A1 (es) |
| AU (1) | AU2013228315A1 (es) |
| CA (1) | CA2865882A1 (es) |
| CO (1) | CO7091180A2 (es) |
| EA (1) | EA201491640A1 (es) |
| HK (1) | HK1200738A1 (es) |
| IN (1) | IN2014DN06939A (es) |
| MX (1) | MX2014010574A (es) |
| PH (1) | PH12014501853A1 (es) |
| SG (1) | SG11201404915SA (es) |
| TW (1) | TW201343201A (es) |
| WO (1) | WO2013133448A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JP2018174986A (ja) * | 2017-04-03 | 2018-11-15 | 花王株式会社 | 吸収構造体及びそれを備えた吸収性物品 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5472711A (en) * | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| JP4170032B2 (ja) | 2002-07-12 | 2008-10-22 | 本多通信工業株式会社 | 光分岐器及びｏ／ｅ変換コネクタ |
| US20060228413A1 (en) * | 2005-02-28 | 2006-10-12 | Penwest Pharmaceuticals Co. | Controlled release venlafaxine formulations |
| CA2652981C (en) | 2006-10-10 | 2012-05-01 | Penwest Pharmaceuticals Co. | Robust sustained release formulations |
| KR20100126452A (ko) * | 2008-02-28 | 2010-12-01 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 난용성 약물용 약학적 조성물 |
| WO2010079506A2 (en) * | 2008-06-23 | 2010-07-15 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of aripiprazole |
| WO2011032882A1 (en) * | 2009-09-15 | 2011-03-24 | Ratiopharm Gmbh | Orally disintegrating pharmaceutical dosage form containing aripiprazole |
-
2013
- 2013-03-05 AR ARP130100712A patent/AR090245A1/es unknown
- 2013-03-05 TW TW102107618A patent/TW201343201A/zh unknown
- 2013-03-06 CN CN201380013047.5A patent/CN104159949A/zh active Pending
- 2013-03-06 EP EP13712944.1A patent/EP2822989A1/en not_active Withdrawn
- 2013-03-06 WO PCT/JP2013/056881 patent/WO2013133448A1/en not_active Ceased
- 2013-03-06 KR KR1020147027554A patent/KR20140131987A/ko not_active Withdrawn
- 2013-03-06 EA EA201491640A patent/EA201491640A1/ru unknown
- 2013-03-06 JP JP2014543382A patent/JP2015509482A/ja active Pending
- 2013-03-06 AU AU2013228315A patent/AU2013228315A1/en not_active Abandoned
- 2013-03-06 CA CA2865882A patent/CA2865882A1/en not_active Abandoned
- 2013-03-06 IN IN6939DEN2014 patent/IN2014DN06939A/en unknown
- 2013-03-06 US US14/383,401 patent/US20150037424A1/en not_active Abandoned
- 2013-03-06 SG SG11201404915SA patent/SG11201404915SA/en unknown
- 2013-03-06 HK HK15101485.3A patent/HK1200738A1/xx unknown
- 2013-03-06 MX MX2014010574A patent/MX2014010574A/es not_active Application Discontinuation
-
2014
- 2014-08-15 PH PH12014501853A patent/PH12014501853A1/en unknown
- 2014-10-06 CO CO14220343A patent/CO7091180A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865882A1 (en) | 2013-09-12 |
| AR090245A1 (es) | 2014-10-29 |
| EP2822989A1 (en) | 2015-01-14 |
| US20150037424A1 (en) | 2015-02-05 |
| PH12014501853A1 (en) | 2014-11-17 |
| KR20140131987A (ko) | 2014-11-14 |
| HK1200738A1 (en) | 2015-08-14 |
| CO7091180A2 (es) | 2014-10-21 |
| SG11201404915SA (en) | 2014-10-30 |
| EA201491640A1 (ru) | 2015-01-30 |
| IN2014DN06939A (es) | 2015-04-10 |
| TW201343201A (zh) | 2013-11-01 |
| CN104159949A (zh) | 2014-11-19 |
| WO2013133448A1 (en) | 2013-09-12 |
| JP2015509482A (ja) | 2015-03-30 |
| AU2013228315A1 (en) | 2014-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1211468A1 (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
| UA114907C2 (uk) | Гетероциклільні сполуки як інгібітори mek | |
| EP4592275A3 (en) | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | |
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| WO2015075745A3 (en) | Turmeric extract containing soft pastilles | |
| WO2012021715A3 (en) | Stable formulations of linaclotide | |
| HK1208441A1 (en) | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists | |
| WO2015056094A3 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
| PH12015501312A1 (en) | Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient | |
| PH12016500865A1 (en) | Composite formulation comprising tadalafil and amlodipine | |
| WO2014081581A3 (en) | Highly loaded amorphous efavirenz composition and process for preparing the same | |
| ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| WO2013128419A3 (en) | Pharmaceutical compositions comprising boronic acid compounds | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| PH12017502149A1 (en) | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester | |
| PH12014501853A1 (en) | Sustained release oral solid preparation | |
| EP2722322B8 (en) | 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient | |
| WO2014006636A3 (en) | Stable compositions of fesoterodine | |
| WO2012119102A3 (en) | Homeopathic therapeutic method and compositions | |
| WO2012010938A3 (en) | Pharmaceutical composition of cefditoren pivoxil | |
| IN2012CH05549A (es) | ||
| WO2015079415A9 (en) | Amorphous cobicistat solid dispersion | |
| WO2014184248A3 (en) | Trpa1 antagonist compounds | |
| WO2012169345A3 (en) | External skin preparation and production method of same | |
| HK1193977A (en) | Homeopathic therapeutic method and compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |